340 related articles for article (PubMed ID: 22970888)
1. The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB₁- and FAAH-independent mechanisms.
Bosier B; Muccioli GG; Lambert DM
Br J Pharmacol; 2013 Jun; 169(4):794-807. PubMed ID: 22970888
[TBL] [Abstract][Full Text] [Related]
2. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of cue-induced reinstatement of nicotine seeking by URB597 through cannabinoid CB1 receptor in rats.
Forget B; Guranda M; Gamaleddin I; Goldberg SR; Le Foll B
Psychopharmacology (Berl); 2016 May; 233(10):1823-8. PubMed ID: 26864774
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Fatty Acid Amide Hydrolase Improves Depressive-Like Behaviors Independent of Its Peripheral Antinociceptive Effects in a Rat Model of Neuropathic Pain.
Jiang HX; Ke BW; Liu J; Ma G; Hai KR; Gong DY; Yang Z; Zhou C
Anesth Analg; 2019 Aug; 129(2):587-597. PubMed ID: 29863609
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of fatty acid amide hydrolase activates Nrf2 signalling and induces heme oxygenase 1 transcription in breast cancer cells.
Li H; Wood JT; Whitten KM; Vadivel SK; Seng S; Makriyannis A; Avraham HK
Br J Pharmacol; 2013 Oct; 170(3):489-505. PubMed ID: 23347118
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid CB
Leonard MZ; Alapafuja SO; Ji L; Shukla VG; Liu Y; Nikas SP; Makriyannis A; Bergman J; Kangas BD
J Pharmacol Exp Ther; 2017 Dec; 363(3):314-323. PubMed ID: 28947487
[TBL] [Abstract][Full Text] [Related]
7. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
Kinsey SG; Long JZ; O'Neal ST; Abdullah RA; Poklis JL; Boger DL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2009 Sep; 330(3):902-10. PubMed ID: 19502530
[TBL] [Abstract][Full Text] [Related]
8. Effects of fatty acid amide hydrolase inhibitor URB597 in a rat model of trauma-induced long-term anxiety.
Danandeh A; Vozella V; Lim J; Oveisi F; Ramirez GL; Mears D; Wynn G; Piomelli D
Psychopharmacology (Berl); 2018 Nov; 235(11):3211-3221. PubMed ID: 30251159
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice.
Nozaki C; Markert A; Zimmer A
Eur Neuropsychopharmacol; 2015 Aug; 25(8):1388-96. PubMed ID: 25910421
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms.
Spradley JM; Guindon J; Hohmann AG
Pharmacol Res; 2010 Sep; 62(3):249-58. PubMed ID: 20416378
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between liver antioxidant and the endocannabinoid systems after chronic administration of the FAAH inhibitor, URB597, to hypertensive rats.
Biernacki M; Łuczaj W; Gęgotek A; Toczek M; Bielawska K; Skrzydlewska E
Toxicol Appl Pharmacol; 2016 Jun; 301():31-41. PubMed ID: 27086176
[TBL] [Abstract][Full Text] [Related]
12. Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat.
Cippitelli A; Cannella N; Braconi S; Duranti A; Tontini A; Bilbao A; Defonseca FR; Piomelli D; Ciccocioppo R
Psychopharmacology (Berl); 2008 Jul; 198(4):449-60. PubMed ID: 18446329
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.
Fegley D; Gaetani S; Duranti A; Tontini A; Mor M; Tarzia G; Piomelli D
J Pharmacol Exp Ther; 2005 Apr; 313(1):352-8. PubMed ID: 15579492
[TBL] [Abstract][Full Text] [Related]
14. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
Russo R; Loverme J; La Rana G; Compton TR; Parrott J; Duranti A; Tontini A; Mor M; Tarzia G; Calignano A; Piomelli D
J Pharmacol Exp Ther; 2007 Jul; 322(1):236-42. PubMed ID: 17412883
[TBL] [Abstract][Full Text] [Related]
15. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.
Haller VL; Stevens DL; Welch SP
Eur J Pharmacol; 2008 Dec; 600(1-3):50-8. PubMed ID: 18762181
[TBL] [Abstract][Full Text] [Related]
16. Chronic treatment with URB597 ameliorates post-stress symptoms in a rat model of PTSD.
Fidelman S; Mizrachi Zer-Aviv T; Lange R; Hillard CJ; Akirav I
Eur Neuropsychopharmacol; 2018 May; 28(5):630-642. PubMed ID: 29519609
[TBL] [Abstract][Full Text] [Related]
17. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.
Moreira FA; Kaiser N; Monory K; Lutz B
Neuropharmacology; 2008 Jan; 54(1):141-50. PubMed ID: 17709120
[TBL] [Abstract][Full Text] [Related]
18. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition.
Scherma M; Medalie J; Fratta W; Vadivel SK; Makriyannis A; Piomelli D; Mikics E; Haller J; Yasar S; Tanda G; Goldberg SR
Neuropharmacology; 2008 Jan; 54(1):129-40. PubMed ID: 17904589
[TBL] [Abstract][Full Text] [Related]
19. Effects of fatty acid amide hydrolase (FAAH) inhibitors on working memory in rats.
Panlilio LV; Thorndike EB; Nikas SP; Alapafuja SO; Bandiera T; Cravatt BF; Makriyannis A; Piomelli D; Goldberg SR; Justinova Z
Psychopharmacology (Berl); 2016 May; 233(10):1879-88. PubMed ID: 26558620
[TBL] [Abstract][Full Text] [Related]
20. The cannabinoid transporter inhibitor OMDM-2 reduces social interaction: Further evidence for transporter-mediated endocannabinoid release.
Seillier A; Giuffrida A
Neuropharmacology; 2018 Mar; 130():1-9. PubMed ID: 29169961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
